论文部分内容阅读
应用ＳＤ２００型骨矿物测定仪测定了１８名健康妇女及２３例高催乳素血症患者的尺、挠骨骨密度，同时测定了血清催乳素（ＰＲＬ）、雌二醇（Ｅ２）、睾酮（Ｔ）、钙（Ｃａ）、磷（Ｐ）及碱性磷酸酶（ＡＫＰ），并观察溴隐亭治疗前后的变化。结果显示，患者的ＰＲＬ升高，Ｅ２减低而Ｔ、Ｃａ、Ｐ及ＡＫＰ无变化，骨密度减低，且与ＰＲＬ呈负相关，与Ｅ２呈正相关。经溴隐亭治疗后ＰＲＬ下降，Ｅ２升高，骨密度逐渐恢复。表明长期高催乳素血症会导致骨密度下降，原因是高ＲＰＬ抑制了垂体－性腺轴，卵巢功能减低，雌激素分泌减少导致了骨质疏松；溴隐亭治疗后，骨密度可得到较大程度的恢复。
The bone mineral density (BMD) in 18 healthy women and 23 patients with hyperprolactinemia were measured by SD200 bone mineral analyzer. Serum prolactin (PRL), estradiol (E2), testosterone (T ), Calcium (Ca), phosphorus (P) and alkaline phosphatase (AKP). The changes of bromocriptine before and after treatment were observed. The results showed that patients with PRL increased, E2 decreased while T, Ca, P and AKP no change in bone mineral density decreased, and was negatively correlated with PRL, and E2 was positively correlated. PRL decreased after bromocriptine treatment, E2 increased, bone mineral density gradually recovered. Suggests that long-term hyperprolactinemia leads to a decrease in bone mineral density due to the high RPL inhibition of the pituitary-gonad axis, reduced ovarian function, reduced estrogen secretion leading to osteoporosis; and greater bone mineral density after bromocriptine treatment The degree of recovery.